oleoylestrone

Small moleculeexperimental

Oleoyl-estrone (OE), or estrone 3-oleate, is a fatty acid ester of estrone. It is a naturally circulating hormone in animals, including humans. It was studied as a potential weight-loss drug, but failed to show benefit in clinical trials. It was first reported in 1996 to cause a body fat loss effect in rats in the International Journal of Obesity and Related Metabolic Disorders. The animal research has all been conducted by the Nitrogen-Obesity Research Group of the University of Barcelona. — Wikipedia

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 2006 (NCT00449202)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCCCC/C=C\CCCCCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Mol. weight
534.83 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • estrone 3-oleate
  • estrone 3-oleate
  • estrone monooleate
  • estrone monooleate
  • estrone oleic acid ester
  • estrone oleic acid ester
  • merlin-2
  • mp-101
  • mp-101
  • oe
  • oe
  • oleoylestrone
  • oleoylestrone
  • oleoyl estrone
  • oleoyl estrone
  • oleoyl estrone
  • oleoyl-estrone
  • oleoyl-estrone
  • oleoyl-estrone
  • oleoyl-estrone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03044249Phase 2May 4, 2017Mediti Pharma Inc.
NCT00449254Phase 2Oct 1, 2006Manhattan Pharmaceuticals
NCT00449202Phase 2Jun 1, 2006Manhattan Pharmaceuticals
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Manhattan PharmaceuticalsFor profit2212006
Mediti Pharma Inc.For profit1112017
2 organizations
Page 1 / 1